These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 12537007)

  • 1. Occupancy of dopamine D2 receptors in the mouse brain measured using ultra-high-resolution single-photon emission tomography and [123]IBF.
    Acton PD; Hou C; Kung MP; Plössl K; Keeney CL; Kung HF
    Eur J Nucl Med Mol Imaging; 2002 Nov; 29(11):1507-15. PubMed ID: 12537007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantification of dopamine transporters in the mouse brain using ultra-high resolution single-photon emission tomography.
    Acton PD; Choi SR; Plössl K; Kung HF
    Eur J Nucl Med Mol Imaging; 2002 May; 29(5):691-8. PubMed ID: 11976810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ultra-high resolution single photon emission tomography imaging of the mouse striatum.
    Acton PD; Kung MP; Hou C; Plössl K; Keeney C; Kung HF
    Eur J Nucl Med Mol Imaging; 2002 Mar; 29(3):446. PubMed ID: 12002724
    [No Abstract]   [Full Text] [Related]  

  • 4. Potentials and pitfalls using high affinity radioligands in PET and SPET determinations on regional drug induced D2 receptor occupancy--a simulation study based on experimental data.
    Olsson H; Farde L
    Neuroimage; 2001 Oct; 14(4):936-45. PubMed ID: 11554812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Localization of IBF as a D-2 dopamine receptor imaging agent in nonhuman primates.
    Billings JJ; Guo YZ; Kung MP; Kung HF
    Eur J Nucl Med; 1993 Dec; 20(12):1146-53. PubMed ID: 8299649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride.
    Yokoi F; Gründer G; Biziere K; Stephane M; Dogan AS; Dannals RF; Ravert H; Suri A; Bramer S; Wong DF
    Neuropsychopharmacology; 2002 Aug; 27(2):248-59. PubMed ID: 12093598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Phase 1 clinical study of 123I-IBF, a new radioligand for evaluating dopamine D2 receptor with SPECT (I); biodistribution and dosimetry].
    Yonekura Y; Sadato N; Tsuchida T; Uematsu H; Nakamura S; Yamamoto K; Ishii Y
    Kaku Igaku; 1999 Feb; 36(2):145-53. PubMed ID: 10213982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Phase 1 clinical study of 123I-IBF, a new radioligand for evaluating Dopamine D2 receptor with SPECT (II); pharmacokinetics study and quantification in the brain].
    Yonekura Y; Sadato N; Tsuchida T; Uematsu H; Nakamura S; Onishi Y; Yamamoto K; Ishii Y
    Kaku Igaku; 1999 Feb; 36(2):155-68. PubMed ID: 10213983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The characterization of IBF as a new selective dopamine D-2 receptor imaging agent.
    Kung MP; Kung HF; Billings J; Yang Y; Murphy RA; Alavi A
    J Nucl Med; 1990 May; 31(5):648-54. PubMed ID: 2140409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Within-subject comparison of striatal D2 receptor occupancy measurements using [123I]IBZM SPECT and [11C]Raclopride PET.
    Catafau AM; Suarez M; Bullich S; Llop J; Nucci G; Gunn RN; Brittain C; Laruelle M;
    Neuroimage; 2009 Jun; 46(2):447-58. PubMed ID: 19233294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of [123I]IBZM pinhole SPECT for the detection of striatal dopamine D2 receptor availability in rats.
    Scherfler C; Scholz SW; Donnemiller E; Decristoforo C; Oberladstätter M; Stefanova N; Diederen E; Virgolini I; Poewe W; Wenning GK
    Neuroimage; 2005 Feb; 24(3):822-31. PubMed ID: 15652317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simultaneous SPECT studies of pre- and postsynaptic dopamine binding sites in baboons.
    Dresel SH; Kung MP; Huang XF; Plössl K; Hou C; Meegalla SK; Patselas G; Mu M; Saffer JR; Kung HF
    J Nucl Med; 1999 Apr; 40(4):660-6. PubMed ID: 10210226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carbon-11 epidepride: a suitable radioligand for PET investigation of striatal and extrastriatal dopamine D2 receptors.
    Langer O; Halldin C; Dollé F; Swahn CG; Olsson H; Karlsson P; Hall H; Sandell J; Lundkvist C; Vaufrey F; Loc'h C; Crouzel C; Mazière B; Farde L
    Nucl Med Biol; 1999 Jul; 26(5):509-18. PubMed ID: 10473189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Striatal and temporal cortical D2/D3 receptor occupancy by olanzapine and sertindole in vivo: a [123I]epidepride single photon emission tomography (SPET) study.
    Bigliani V; Mulligan RS; Acton PD; Ohlsen RI; Pike VW; Ell PJ; Gacinovic S; Kerwin RW; Pilowsky LS
    Psychopharmacology (Berl); 2000 Jun; 150(2):132-40. PubMed ID: 10907666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo measurement of haloperidol affinity to dopamine D2/D3 receptors by [123I]IBZM and single photon emission computed tomography.
    Videbaek C; Toska K; Friberg L; Holm S; Angelo HR; Knudsen GM
    J Cereb Blood Flow Metab; 2001 Jan; 21(1):92-7. PubMed ID: 11149673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolism of [123I]epidepride may affect brain dopamine D2 receptor imaging with single-photon emission tomography.
    Bergström KA; Yu M; Kuikka JT; Akerman KK; Hiltunen J; Lehtonen J; Halldin C; Tiihonen J
    Eur J Nucl Med; 2000 Feb; 27(2):206-8. PubMed ID: 10755727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rostrocaudal gradients of dopamine D2/3 receptor binding in striatal subregions measured with [(11)C]raclopride and high-resolution positron emission tomography.
    Alakurtti K; Johansson JJ; Tuokkola T; Någren K; Rinne JO
    Neuroimage; 2013 Nov; 82():252-9. PubMed ID: 23727314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Test-retest reliability of central [11C]raclopride binding at high D2 receptor occupancy. A PET study in haloperidol-treated patients.
    Nyberg S; Farde L; Halldin C
    Psychiatry Res; 1996 Oct; 67(3):163-71. PubMed ID: 8912956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measurement of striatal and thalamic dopamine D2 receptor binding with 11C-raclopride.
    Hirvonen J; Aalto S; Lumme V; Någren K; Kajander J; Vilkman H; Hagelberg N; Oikonen V; Hietala J
    Nucl Med Commun; 2003 Dec; 24(12):1207-14. PubMed ID: 14627846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Phase 2 clinical study of 123I-IBF, a dopamine D2 receptor imaging agent, to evaluate clinical efficacy and safety in Parkinson's disease and Parkinson syndromes].
    Torizuka K; Mizuno Y; Kubo A; Konishi J; Yonekura Y; Hatazawa J; Momose T; Murata M; Amano T; Fukuyama H; Kuwabara Y
    Kaku Igaku; 1999 Oct; 36(8):845-64. PubMed ID: 10586546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.